EASL - The International Liver Congress 2015 50th Annual Meeting of the European Association for the Study of the Liver London, United Kingdom April 22-26

Conference Reports for NATAP


EASL - The International Liver Congress 2015 50th Annual Meeting of the European Association for the Study of the Liver Vienna, Austria April 22-26

	The Pharmacokinetics of GS-5816, a Pangenotypic HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects With Severe Renal Impairment - (12/21/15) EACS aging-related presentations - (12/18/15) Genital Inflammation & HIV Acqusition Associated in Women.....STIs also associated with Inflammation & HIV Acquisition - new study - (06/26/15) INTERFERON AND RIBAVIRIN-FREE THERAPY WITH SOFOSBUVIR AND DACLATASVIR IN A REAL-LIFE COHORT OF DIFFICULT-TO-TREAT HIV/HCV-COINFECTED PATIENTS WITH AND WITHOUT PORTAL HYPERTENSION - (07/13/15) Safety, efficacy and tolerability of half-dose Sofosbuvir plus Simeprevir in treatment of Hepatitus C in patients with end stage renal disease - (07/13/15) WHO Global Hepatitis strategy in the making - (06/26/15) Summary from EASL 2015 for Hepatitis C All oral HCV DAA therapy on its way to optimization: still much to learn. - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (05/22/15) SURVIVAL OF PATIENTS INFECTED BY CHRONIC HEPATITIS C AND F0F1 FIBROSIS AT BASELINE AFTER A 15 YEARS FOLLOW-UP - (09/08/15) Merck at EASL 2015 - (05/22/15) PRECLINICAL CHARACTERISATION OF MIV-802, A NOVEL URIDINE NUCLEOTIDE HCV NS5B POLYMERASE INHIBITOR, FOR TREATMENT OF HEPATITIS C VIRUS INFECTION - (05/18/15) IDUs/Intervention Model Global - What is needed to control Hepatitis C (HCV) in different epidemiological settings? - (05/18/15) UNDERSTANDING AND PREVENTING THE HCV EPIDEMIC AMONG MEN WHO HAVE SEX WITH MEN IN THE UK: A MATHEMATICAL MODELLING ANALYSIS - (05/18/15) The Impact of Ribavirin on Real World Adherence and Discontinuation Rates in HCV Patients Treated with Sofosbuvir + Simeprevir - (05/18/15) Exposure-Response Analyses for Efficacy (SVR12) for the Direct Acting Antiviral Regimen of Paritaprevir/r, Ombitasvir with Dasabuvir ± Ribavirin in Subjects with HCV Genotype 1 Infection - (05/18/15) PHARMACOKINETICS OF PARITAPREVIR, OMBITASVIR, DASABUVIR, RITONAVIR AND RIBAVIRIN IN SUBJECTS WITH HCV GENOTYPE 1 INFECTION IN PHASE 3 STUDIES - (05/18/15) Adherence to Ombitasvir/Paritaprevir/r, Dasabuvir, and Ribavirin is >98% in the SAPPHIRE-I and SAPPHIRE-II Trials - (05/18/15) Public Health Impact of HCV Screening and Treatment in the French Baby-Boomer Population - (05/18/15) How should scale up of HCV antiviral treatment be prioritized? A cost-effectiveness analysis including individual and population prevention benefits - (05/15/15) Achillion at EASL 2015 - (05/15/15) HEALTHCARE ECONOMICS / SVR Improves Health, Mortality / Early HCV Therapy Prefer - (05/14/15) Cohort Studies at EASL 2015 - (05/14/15) Gilead at EASL 2015 - (05/12/15) NS5A Mutations/Resistance - (05/11/15) GS-9857 Pangenotypic Protease Inhibitor + SOF/GS5816 for 6/8 Weeks - (05/11/15) ABT530+ABT493 Pangenotypic in Phase 2B - (05/11/15) WHO moves to improve access to lifesaving medicines for hepatitis C, drug-resistant TB and cancers - (05/11/15) Harvoni Post-Transplant - (05/11/15) Safety and efficacy of Sofosbuvir-containing regimens in the French cohort- ANRS CO22 HEPATHER - (05/11/15) Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: data from the French cohort- ANRS CO22 HEPATHER - (05/11/15) Abbvie at EASL 2015 - Healthcare Economics, Clinical Trials - (05/11/15) J&J at EASL - (05/11/15) BMS at EASL - (05/11/15) HCC Risk Scores: Application of the CU-HCC, GAG-HCC, and PAGE-B Scores to Chronic Hepatitis B Patients Treated With Tenofovir Disoproxil Fumarate (TDF) - (05/08/15) New HCV Drugs new nukes-NS5A/Protease Inhibitors - (05/08/15) Merck HCV Nuk MK3682 7-Day Monotherapy - (05/05/15) Preclinical Characterization of AL-335, a Potent Uridine Based Nucleoside Polymerase Inhibitor for the Treatment of Chronic Hepatitis C - (05/05/15) Derisking the Potential for Mitochondrial Toxicity of Nucleoside Analogs - (05/05/15) Effect of Baseline Factors on Response to the Fixed-Dose Combination Of Daclatasvir, Asunaprevir and Beclabuvir in Non-Cirrhotic Patients with HCV Genotype 1 Infection - (05/05/15) Effect of Baseline Factors on Response to the Fixed-Dose Combination of Daclatasvir, Asunaprevir, and Beclabuvir, With or Without Ribavirin, in Patients With HCV Genotype 1 Infection and Cirrhosis - (05/05/15) The Pharmacokinetics of Beclabuvir (BMS-791325) When Administered in Combination With Daclatasvir and Asunaprevir in Treatment-naive Patients With or Without Cirrhosis Infected With HCV Genotype 1 - (05/05/15) The Effect of Renal Impairment on Multiple-dose Pharmacokinetics of the Fixed-dose Combination of Daclatasvir/Asunaprevir/Beclabuvir - (05/05/15) Safety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C Infected Patients with Reduced Renal Function: Real-World Experience from HCV-TARGET - (05/05/15) Evaluation of Drug-Drug Interactions Between the Fixed-Dose Combination of Daclatasvir/Asunaprevir/Beclabuvir and Methadone or Buprenorphine/Naloxone - (05/05/15) Potent Antiviral Activity of ABT-493 and ABT-530 With 3-Day Monotherapy in Patients With and Without Compensated Cirrhosis With Hepatitis C Virus (HCV) Genotype 1 Infection - (05/04/15) Add-on Peginterferon Alfa-2a significantly reduces HBsAg levels in HBeAg-negative, genotype D chronic hepatitis B patients fully suppressed on nucleot(s)ide analogue treatment The HERMES Study - (05/04/15) Steady-State Pharmacokinetics and Safety of Co-administration of Pan-Genotypic Direct Acting Protease Inhibitor ABT-493 with Pan-Genotypic NS5A Inhibitor ABT-530 in Healthy Adult Subjects - (05/04/15) Advanced Fibrosis is Common in Individuals whose Hepatitis C Has Not Been Diagnosed: Results from the National Health and Nutrition Examination Survey 2001-2012 - (05/04/15) Pharmacokinetics of ABT-493 and ABT-530 is Similar in Healthy Caucasian, Han Chinese, and Japanese Adult Subjects - (05/04/15) 8 HCV DAA Studies in African-Americans - (05/04/15) No Evidence of Pharmacokinetic Drug-Drug Interaction in Healthy Subjects Between Coadministered Grazoprevir (MK-5172)/Elbasvir (MK-8742) and Sofosbuvir - (05/04/15) Resistance Analysis of Virologic Failures in Hepatitis C Genotype 1-Infected Patients Treated With Grazoprevir + Elbasvir ± Ribavirin: the C-WORTHY Study - (05/04/15) The ASTRAL Studies: Evaluation of SOF/GS-5816 Single-Tablet Regimen for the Treatment of Genotype 1-6 HCV Infection - (05/04/15) Early versus delayed use of sofosbuvir plus peginterferon/ribavirin therapy in fibrosis patients with hepatitis C virus: a cost-effectiveness analysis - (05/04/15) Resistance Analysis of Treatment-Experienced Genotype 1 and 3 HCV-Infected Patients Treated With Sofosbuvir in Combination With GS-5816 ± Ribavirin for 12 Weeks - (05/04/15) Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of Fibrosing Cholestatic Hepatitis C After Liver Transplantation - (05/04/15) Early Viral Kinetics in Patients With Varying Degrees of Fibrosis and Cirrhosis in the SOLAR-1 Trial - (05/04/15) SVR Reduces Morbidity/Deaths by 5-10 Fold - Abbvie Analysis - Percent of Subjects Experiencing Liver Morbidity Over a Lifetime Horizon with AbbVie 3D (Abt-450/Ritonavir/Ombitasvirand Dasabuvir) Versus No treatment - (04/31/15) Sustained Virologic Response After ACH-3102 and Sofosbuvir Treatment for 8 or 6 Weeks: a Phase 2 "Proxy" Study - (04/31/15) ACH-3422, a Novel Nucleotide Prodrug Inhibitor of HCV NS5B Polymerase - (04/31/15) ACHIEVEMENT OF SVR24 DESPITE THE PRESENCE OF HCV VARIANTS RESISTANT TO FIRST-GENERATION NS5A INHIBITORS IN GENOTYPE-1 HEPATITIS C PATIENTS AFTER 8-WEEK THERAPY OF ACH-3102 IN COMBINATION WITH SOFOSBUVIR - (04/31/15) Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER - (04/31/15) Cost-Effectiveness of Treating Different Stages of Genotype 1 Hepatitis C Virus (GT1-HCV) With Viekira Pak (Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin Compared to No Treatment in the United States - (04/31/15) 100% SVR12 With Ledipasvir/Sofosbuvir ± Ribavirin for 12 Weeks in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Who Previously Failed Protease Inhibitor + Pegylated Interferon-a + Ribavirin Therapy - (04/31/15) 98% SVR12 in Korean and Taiwanese Patients With Chronic Genotype 2 HCV Infection Receiving 12 Weeks of Sofosbuvir Plus Ribavirin: Results From an International, Multicenter Phase 3 Study - (04/31/15) Final evaluation of HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the TRIO network: academic and community treatment of a real-world, heterogeneous population - (04/30/15) Efficacy evaluation of 24 week SOF + RBV in a heterogeneous, real-world population of Genotype 3 HCV; data from the TRIO network - (04/30/15) Comparison of sofosbuvir +/- simeprevir in heterogeneous, real-world populations of HCV patients over 70 years; data from the TRIO network - (04/30/15) Prevalence of Pretreatment NS5A and NS5B Resistance-Associated Variants and Genetic Variation Within HCV Subtypes Across Different Countries/Gilead-Study - (04/30/15) Ledipasvir/Sofosbuvir With Ribavirin Is Safe in >600 Decompensated and Post-Liver Transplantation Patients With HCV Infection: An Integrated Safety Analysis of the SOLAR-1 and SOLAR-2 Trials - (04/29/15) The Prevalence and the Effect of HCV NS5A Resistance-Associated Variants in Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir ± RBV - (04/29/15) Time Course of Hepatic Improvement using the HepQuant® (HQ)-SHUNT Function Test during and after Treatment with Ledipasvir/Sofosbuvir in Liver Transplant Recipients with Allograft Fibrosis or Cirrhosis and Patients with Decompensated Cirrhosis who have not undergone Transplantation - (04/29/15) Effect of Long-Term Viral Suppression With Sofosbuvir + Ribavirin on Hepatic Venous Pressure Gradient in HCV-Infected Patients With Cirrhosis and Portal Hypertension - (04/29/15) Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of HCV in Patients With Severe Liver Disease: Interim Results of a Multicenter Compassionate Use Program - (04/29/15) A Systematic Review of Viral Hepatitis B and C Testing in Europe: shortage of hepatitis screening studies across Europe/barrier to diagnosis, early treatment & prevention - (04/29/15) Evaluation of the Pangenotypic HCV NS3/4A Protease Inhibitor GS-9857 in Healthy Volunteers - (04/29/15) Preclinical Profile of the Pangenotypic HCV NS3/4A Protease Inhibitor GS-9857 - (04/29/15) Ledipasvir/Sofosbuvir for the Treatment of Patients With Chronic Genotype 4 or 5 HCV Infection - (04/29/15) HCV Reinfection in Phase 3 Studies of Sofosbuvir - (04/29/15) Long-Term Persistence of HCV NS5A Variants After Treatment With NS5A Inhibitor Ledipasvir - (04/29/15) A Phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2 - (04/29/15) EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE TO PREVENT VERTICAL TRANSMISSION IN MOTHERS WITH LAMIVUDINE-RESISTANT HBV - (04/29/15) Effect of the combination of the HBV core inhibitor NVR 3-778 with Nucleoside Analogs or other HBV core inhibitors on the inhibition of HBV DNA Replication in HepG2.2.15 cells - (04/29/15) A Phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1 - (04/28/15) Real World Effectiveness and Cost of Simeprevir- and/or Sofosbuvir-based HCV Treatments - (04/28/15) PREDICTORS OF SUSTAINED VIRAL RESPONSE TO 4-6 WEEK DURATION THERAPY WITH LEDIPASVIR + SOFOSBUVIR + GS-9451 +/- GS-9669 IN EARLY AND ADVANCED FIBROSIS (NIH/UMD SYNERGY TRIAL) - (04/28/15) HIGH EFFICACY OF RETREATMENT WITH LEDPASVIR AND SOFOSBUVIR IN HCV PATIENTS WHO FAILED INITIAL SHORT COURSE THERAPY WITH COMBINATION DAA REGIMENS (NIH SYNERGY TRIAL) - (04/28/15) Safety and efficacy of all-oral DAA regimens in HIV-HCV coinfected cirrhotic patients from the prospective ANRS CO13 - HEPAVIH cohort - (04/28/15) Efficacy of the oral Sofosbuvir-based combination in HCV genotype 4-monoinfected patients from the French observational cohort ANRS CO22 HEPATHER - (04/28/15) CAN HEPATITIS C TREATMENT BE SAFELY DELAYED?: EVIDENCE FROM THE VETERANS ADMINISTRATION HEALTHCARE SYSTEM - (04/28/15) The Value of Survival Benefits from Treating Hepatitis C at Different Fibrosis Stages with All-Oral, Interferon-Free Therapy Relative to 'Watchful Waiting' - (04/28/15) Reduction in Annual Medical Costs with Early Treatment of HCV Using Abbvie 3D (AbT-450/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin in the United States - (04/28/15) Grazoprevir/Elbasvir plus Ribavirin For Chronic HCV Genotype-1 Infection After Failure of Combination Therapy Containing a Direct-Acting Antiviral Agent - (04/28/15) EFFICACY OF AN 8-WEEK REGIMEN OF GRAZOPREVIR PLUS ELBASVIR WITH AND WITHOUT RIBAVIRIN IN TREATMENT-NAIVE, NONCIRRHOTIC HCV GENOTYPE 1B INFECTION - (04/28/15) A Single-Tablet Regimen of Ledipasvir/Sofosbuvir for 12 Weeks in HCV Genotype 1- or 4-Infected Patients With HIV-1 Coinfection: the Phase 3 ION-4 Study - (04/28/15) Merck Phase 3 clinical trials evaluating grazoprevir/elbasvir, C-EDGE program, - (04/28/15) Real-world effectiveness of Ledipasvir/Sofosbuvir 8 weeks chronic HCV treatment - (04/28/15) Ledipasvir/Sofosbuvir With Ribavirin Is Safe in >600 Decompensated and Post-Liver Transplantation Patients With HCV Infection: An Integrated Safety Analysis of the SOLAR-1 and SOLAR-2 Trials - (04/28/15) OMBITASVIR/PARITAPREVIR/RITONAVIR FOR TREATMENT OF HCV GENOTYPE 1B IN JAPANESE PATIENTS WITH OR WITHOUT CIRRHOSIS: RESULTS FROM GIFT-I - (04/28/15) ALL-ORAL 12-WEEK COMBINATION TREATMENT WITH DACLATASVIR AND SOFOSBUVIR IN TREATMENT-EXPERIENCED PATIENTS INFECTED WITH HCV GENOTYPE 3: A SUBANALYSIS OF THE ALLY-3 PHASE 3 STUDY - (04/28/15) Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients with Advanced Cirrhosis or Post-transplant Recurrence: ALLY-1 Phase 3 Study - (04/28/15) On-Treatment HCV RNA as a Predictor of Sustained Virologic Response in HCV Genotype 3-Infected Patients Treated With Daclatasvir and Sofosbuvir: A Subanalysis of the Phase 3 ALLY-3 Study - (04/28/15) Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes 1-4 in HIV-HCV Coinfection: The ALLY-2 Study - (04/28/15) CANCER RATES IN PATIENTS WITH CHRONIC HEPATITIS C IN A LARGE U.S. HEALTH MAINTENANCE ORGANIZATION (Kaiser)....HCV Linked to Increased Cancer Risks/Not just liver cancer - (04/27/15) Sofosbuvir Plus Peg-IFN/RBV for 12 Weeks vs Sofosbuvir/RBV for 16 or 24 Weeks in Genotype 3 HCV-Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study - (04/27/15) SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR FOR TREATING HCV GT1 INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE: THE RUBY-I STUDY - (04/27/15) Malachite-I Phase 3b Trial of Ombitasvir/Paritaprevir/r and Dasabuvir ± Ribavirin or Telaprevir + Peginterferon/Ribavirin in Treatment-Naïve Adults With Hc v Genotype 1 - (04/27/15) Malachite-II : Phase 3b Trial of Ombitasvir/Paritaprevir/r and Dasabuvir + Ribavirin or Telaprevir + Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With Hcv Genotype 1 - (04/24/15) The association of Sofosbuvir and Daclatasvir for treating severe recurrence of HCV infection after liver transplantation - (04/27/15) No Significant Interaction Among Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir and Sofosbuvir - (04/27/15) Healthcare Costs by Stage of Liver Disease in Chronic Hepatitis C Patients in the United States - (04/27/15) THE GLOBAL AND REGIONAL BURDEN OF LIVER DISEASE, 2013: deaths due to HCV doubled from 1990 to 2013 - (04/27/15) HCV Screening/treatment in UK Prisons Can be Cost-Effective - IS INCREASED HCV CASE-FINDING COMBINED WITH 8 OR 12 WEEK INTERFERON-FREE DIRECT-ACTING ANTIVIRAL TREATMENT COST EFFECTIVE IN UK PRISONS? A COST UTILITY ANALYSIS INCLUDING TREATMENT AS PREVENTION BENEFITS - (04/27/15) SAFETY AND EFFICACY OF THE COMBINATION DACLATASVIR-SOFOSBUVIR IN HCV GENOTYPE 1-MONO-INFECTED PATIENTS FROM THE FRENCH OBSERVATIONAL COHORT ANRS CO22 HEPATHER - (04/27/15) Phase 3b Studies (5 Years post-treatment) to Assess Long-Term Clinical Outcomes in HCV GT1-Infected Patients Treated With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin - (04/27/15) A Single Subcutaneous Dose of 2 mg/kg or 4 mg/kg of RG-101, a Galnac-Conjugated Oligonucleotide with Antagonist Activity against miR-122, Results in Significant Viral Load Reductions in Chronic Hepatitis C Patients - (04/27/15) Pharmacokinetics of Miravirsen, a miR-122 Inhibitor, Predict the Prolonged Viral Load Reduction in Treatment Naive Genotype 1 HCV-Infected Patients - (04/27/15) CANCER RATES IN PATIENTS WITH CHRONIC HEPATITIS C IN A LARGE U.S. HEALTH MAINTENANCE ORGANIZATION.....cancer rate 2.5 times higher among HCV+, even when liver cancer is excluded rate is almost 2 times higher - (04/27/15) LONG-TERM FOLLOW-UP OF TREATMENT-EMERGENT RESISTANCE-ASSOCIATED VARIANTS IN NS3, NS5A AND NS5B WITH PARITAPREVIR/r-, OMBITASVIR- AND DASABUVIR-BASED REGIMENS - (04/24/15) Safety and Efficacy of Short-Duration Treatment With GS-9857 Combined With Sofosbuvir/GS-5816 in Treatment-Naïve and DAA-Experienced Genotype 1 Patients With and Without Cirrhosis - (04/24/15) Implications of Baseline HCV RNA Level and Intrapatient Viral Load Variability on OBV/PTV/r + DSV 12-Week Treatment Outcomes - (04/24/15) An Open-Label Study to Evaluate the Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults with Chronic HCV Genotype 4 Infection in Egypt (AGATE-II) - (04/24/15) Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV Genotypes 1 and 3 - (04/24/15) DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 3 INFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM - (04/24/15) DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HIV-HCV COINFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM - (04/24/15) Malachite-I Phase 3b Trial of Ombitasvir/Paritaprevir/r and Dasabuvir ± Ribavirin or Telaprevir + Peginterferon/Ribavirin in Treatment-Naïve Adults With Hcv Genotype 1 - (04/24/15) Simeprevir plus daclatasvir and sofosbuvir in treatment-naïve and treatment-experienced patients with chronic hepatitis C virus genotype 1 or 4 infection and decompensated liver disease: interim results from the Phase II IMPACT study - (04/24/15) THE PHASE 3 C-EDGE TREATMENT-NAIVE (TN) STUDY OF A 12-WEEK ORAL REGIMEN OF GRAZOPREVIR (GZR, MK-5172)/ELBASVIR (EBR, MK-8742) IN PATIENTS WITH CHRONIC HCV GENOTYPE (GT) 1, 4, OR 6 INFECTION - (04/24/15) U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C - (04/24/15) Ledipasvir/Sofosbuvir With Ribavirin is Safe and Efficacious in Decompensated and Post-Liver Transplantation Patients With HCV Infection: Preliminary Results of the SOLAR-2 Trial - (04/24/15) Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks - (04/24/15) Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C - (04/24/15) Gilead's Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Disease - (04/24/15) ELECTRON-2 - Ledipasvir/Sofosbuvir Fixed-Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including GT 3 Patients, Decompensated GT 1 Patients, and GT 1 Patients With Prior Sofosbuvir Experience - (04/24/15) Improvement in Liver Function and Non-Invasive Estimates of Liver Fibrosis 48 Weeks after Treatment With Ombitasvir/Paritaprevir/r, Dasabuvir, and Ribavirin in HCV Genotype 1 Patients With Cirrhosis - (04/24/15) High SVR Rates Despite Multiple Negative Predictors in Genotype 1 Patients Receiving Ombitasvir/Paritaprevir/r, Dasabuvir With or Without Ribavirin For 12 and 24 Weeks: Integrated Analysis of Six Phase 3 Trials - (04/24/15) A Randomized, Open-Label Study to Evaluate Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Infection and Cirrhosis (AGATE-I) - (04/23/15) SAFETY AND EFFICACY OF SHORT-DURATION TREATMENT WITH GS-9857 COMBINED WITH SOFOSBUVIR/GS-5816 IN TREATMENT-NAIVE AND DAA-EXPERIENCED GENOTYPE 1 PATIENTS WITH AND WITHOUT CIRRHOSIS - (04/23/15) All Oral HCV Therapy is Safe and Effective in Patients with Decompensated Cirrhosis: Report from HCV-TARGET - (04/23/15) Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes 1-4 in HIV-HCV Coinfection: The ALLY-2 Study - (04/23/15) EFFICACY AND SAFETY OF GRAZOPREVIR AND ELBASVIR IN HEPATITIS C GENOTYPE 1-INFECTED PATIENTS WITH CHILD-PUGH CLASS B CIRRHOSIS (C-SALT PART A) - (04/23/15) On-treatment virologic response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation (OLT): interim data from the Phase II SATURN study - (04/23/15) C-SWIFT: GRAZOPREVIR/ELBASVIR + SOFOSBUVIR IN CIRRHOTIC AND NONCIRRHOTIC, TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION, FOR DURATIONS OF 4, 6 OR 8 WEEKS AND GENOTYPE 3 INFECTION FOR DURATIONS OF 8 OR 12 WEEKS - (04/23/15) C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE - (04/23/15) Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease - (04/23/15) Janssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis - (04/23/15) C-EDGE COINFECTION: PHASE 3 STUDY OF GRAZOPREVIR/ELBASVIR IN PATIENTS WITH HCV/HIV - (04/23/15) C-SCAPE: EFFICACY AND SAFETY OF 12 WEEKS OF GRAZOPREVIR ± ELBASVIR ± RIBAVIRIN IN PATIENTS WITH HCV GT2, 4, 5, OR 6 INFECTION - (04/23/15) A Phase 1 Study to Evaluate the Interaction of HCV NS5B Inhibitor MK-3682 With HCV NS3/4A Protease Inhibitor MK-5172 and HCV NS5A Inhibitor MK-8408 in Healthy Subjects - (04/23/15) EFFICACY AND SAFETY OF GRAZOPREVIR/ELBASVIR +/- RBV FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV G1, G4 OR G6 INFECTION WHO PREVIOUSLY FAILED PEGINTERFERON/RBV: C-EDGE TREATMENT-EXPERIENCED - (04/23/15) C-SALVAGE: GRAZOPREVIR (GZR; MK-5172), ELBASVIR (EBR; MK-8742) AND RIBAVIRIN (RBV) FOR CHRONIC HCV-GENOTYPE 1 (GT1) INFECTION AFTER FAILURE OF DIRECT-ACTING ANTIVIRAL (DAA) THERAPY - (04/23/15) EASL Recommendations on Treatment of Hepatitis C 2015 - (04/22/15) AbbVie to Present New Data from Hepatitis C Clinical Development Program at The International Liver Congress™ 2015 - (04/22/15)